Stroke is a significant leading cause of death and disability in the United States(Tsao et al.,2022).Approximately 87% of strokes fall into the ischemic category,mainly caused by arterial blockage(Jayaraj et al.,2019)...Stroke is a significant leading cause of death and disability in the United States(Tsao et al.,2022).Approximately 87% of strokes fall into the ischemic category,mainly caused by arterial blockage(Jayaraj et al.,2019).Although the only FDA-approved effective medication is tissue plasminogen activator(tPA),it should be administrated within 4.5 hours of ischemic stroke.Furthermore,tPA has been an integral part of managing acute ischemic stro ke.展开更多
Neurodegenerative diseases are often misdiagnosed,especially when the diagnosis is based solely on clinical symptoms.The p75 neurotrophic receptor(p75^(NTR))has been studied as an index of sensory and motor nerve deve...Neurodegenerative diseases are often misdiagnosed,especially when the diagnosis is based solely on clinical symptoms.The p75 neurotrophic receptor(p75^(NTR))has been studied as an index of sensory and motor nerve development and maturation.Its cleavable extracellular domain(ECD)is readily detectable in various biological fluids including plasma,serum and urine.There is evidence for increased p75NTR ECD levels in neurodegenerative diseases such as Alzheimer’s disease,amyotrophic lateral sclerosis,age-related dementia,schizophrenia,and diabetic neuropathy.Whether p75^(NTR) ECD could be used as a biomarker for diagnosis and/or prognosis in these disorders,and whether it could potentially lead to the development of targeted therapies,remains an open question.In this review,we present and discuss published studies that have evaluated the relevance of this emerging biomarker in the context of various neurodegenerative diseases.We also highlight areas that require further investigation to better understand the role of p75^(NTR) ECD in the clinical diagnosis and management of neurodegenerative disorders.展开更多
目的:应用p75NTR进行人食管肿瘤干细胞的分选,并对其生物学特性进行鉴定。方法:对人食管癌标本癌细胞及食管癌细胞株TE-1、Eca109进行培养,应用流式细胞仪检测p75NTR在人食管癌细胞(esophageal cancer cells,ECCs)中的表达,应用磁珠分选...目的:应用p75NTR进行人食管肿瘤干细胞的分选,并对其生物学特性进行鉴定。方法:对人食管癌标本癌细胞及食管癌细胞株TE-1、Eca109进行培养,应用流式细胞仪检测p75NTR在人食管癌细胞(esophageal cancer cells,ECCs)中的表达,应用磁珠分选(MACS)法进行p75NTR阳性细胞与阴性细胞的分选,观察p75NTR阳性细胞的增殖、分化及软琼脂克隆形成能力,并进行裸鼠接种以观察其致瘤能力;应用化疗药物作用于ECCs后检测其中p75NTR阳性细胞与阴性细胞存活率,以评价p75NTR阳性细胞对化疗药物的耐受性。结果:8个食管肿瘤细胞系(株)中,除SHEC-1、SHEC-5未检测到p75NTR阳性细胞外,其余6个细胞系(株)SHEC-4、SHEC-6、SHEC-7、SHEC-8、Eca109、TE-1中均检测到p75NTR阳性细胞,阳性细胞比例分别为2.71%、0.32%、3.35%、1.13%、2.15%、0.45%。与阴性及未分选细胞相比,MACS分选后的p75NTR阳性细胞具有较强的增殖能力,具有分化产生其他表型细胞的能力,在软琼脂中具有较强的克隆形成能力(P<0.01);行裸鼠接种时,p75NTR阳性细胞表现出较强的致瘤性,其中SHEC-7细胞只需2×103个即可致瘤,其致瘤能力是未分选细胞的50倍。化疗药物分别作用于p75NTR阳性细胞与阴性细胞48h后,p75NTR阳性细胞的存活比例明显高于阴性细胞(P<0.05)。结论:人食管肿瘤细胞中p75NTR阳性细胞具有自我更新、分化、增殖能力,对化疗药物具有较强的耐受性,并具有较强的致瘤能力,具有肿瘤干细胞的特性。展开更多
基金supported by the UTHSC Bridge funding award (E073005058 Bridge Support-2022)the National Institute of Health (R01-NS09 7800 and R56 NS127924-01) to TI。
文摘Stroke is a significant leading cause of death and disability in the United States(Tsao et al.,2022).Approximately 87% of strokes fall into the ischemic category,mainly caused by arterial blockage(Jayaraj et al.,2019).Although the only FDA-approved effective medication is tissue plasminogen activator(tPA),it should be administrated within 4.5 hours of ischemic stroke.Furthermore,tPA has been an integral part of managing acute ischemic stro ke.
文摘Neurodegenerative diseases are often misdiagnosed,especially when the diagnosis is based solely on clinical symptoms.The p75 neurotrophic receptor(p75^(NTR))has been studied as an index of sensory and motor nerve development and maturation.Its cleavable extracellular domain(ECD)is readily detectable in various biological fluids including plasma,serum and urine.There is evidence for increased p75NTR ECD levels in neurodegenerative diseases such as Alzheimer’s disease,amyotrophic lateral sclerosis,age-related dementia,schizophrenia,and diabetic neuropathy.Whether p75^(NTR) ECD could be used as a biomarker for diagnosis and/or prognosis in these disorders,and whether it could potentially lead to the development of targeted therapies,remains an open question.In this review,we present and discuss published studies that have evaluated the relevance of this emerging biomarker in the context of various neurodegenerative diseases.We also highlight areas that require further investigation to better understand the role of p75^(NTR) ECD in the clinical diagnosis and management of neurodegenerative disorders.
文摘目的:应用p75NTR进行人食管肿瘤干细胞的分选,并对其生物学特性进行鉴定。方法:对人食管癌标本癌细胞及食管癌细胞株TE-1、Eca109进行培养,应用流式细胞仪检测p75NTR在人食管癌细胞(esophageal cancer cells,ECCs)中的表达,应用磁珠分选(MACS)法进行p75NTR阳性细胞与阴性细胞的分选,观察p75NTR阳性细胞的增殖、分化及软琼脂克隆形成能力,并进行裸鼠接种以观察其致瘤能力;应用化疗药物作用于ECCs后检测其中p75NTR阳性细胞与阴性细胞存活率,以评价p75NTR阳性细胞对化疗药物的耐受性。结果:8个食管肿瘤细胞系(株)中,除SHEC-1、SHEC-5未检测到p75NTR阳性细胞外,其余6个细胞系(株)SHEC-4、SHEC-6、SHEC-7、SHEC-8、Eca109、TE-1中均检测到p75NTR阳性细胞,阳性细胞比例分别为2.71%、0.32%、3.35%、1.13%、2.15%、0.45%。与阴性及未分选细胞相比,MACS分选后的p75NTR阳性细胞具有较强的增殖能力,具有分化产生其他表型细胞的能力,在软琼脂中具有较强的克隆形成能力(P<0.01);行裸鼠接种时,p75NTR阳性细胞表现出较强的致瘤性,其中SHEC-7细胞只需2×103个即可致瘤,其致瘤能力是未分选细胞的50倍。化疗药物分别作用于p75NTR阳性细胞与阴性细胞48h后,p75NTR阳性细胞的存活比例明显高于阴性细胞(P<0.05)。结论:人食管肿瘤细胞中p75NTR阳性细胞具有自我更新、分化、增殖能力,对化疗药物具有较强的耐受性,并具有较强的致瘤能力,具有肿瘤干细胞的特性。
